《新股表現》諾輝健康(06606.HK)暗盤高開1.2倍報58.4元
根據輝立交易平台顯示,明天掛牌的諾輝健康(06606.HK)暗盤高開1.2倍報58.4元獲承接,現造79元,較上市價26.66元,飆1.96倍,成交18萬股。
諾輝於2015年11月成立,是內地結直腸癌早期篩查市場先行者,根據弗若斯特沙利文,諾輝專有的非侵入性多靶點FIT-DNA 測試「常衛清」為內地首個兼唯一獲國家藥監局批准的分子癌症篩查測試。「常衛清」的目標客戶為內地1.2億結直腸癌高危人群,可讓用戶居家採集糞便樣本,避免施行具有侵入性手術,同時取得較高測試靈敏度及特異性。
是次來港上市共發售7,659.8萬股,並已引入包括景順、清池資本、博裕及GIC等16名基石投資者,合共認購3,606.25萬股;10%公開發售獲4,132倍超購,啟動回撥機制後佔比增至50%,認購一手中籤率僅2%,股份以招股範圍(22.7-26.66元)上限定價,料集資淨額約18.99億元,主要用於為產品「常衛清」商業化和進一步開發提供資金、為正在進行與計劃進行早期階段管線產品研發提供資金、用作潛在收購或外部引進癌症篩查領域候選產品等。上市聯席保薦人分別為高盛及瑞銀。上市聯席保薦人為高盛及瑞銀。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.